In a report released today, Miki Sogi from Bernstein maintained a Hold rating on Astellas Pharma, with a price target of Yen1,600.00. The company’s shares closed last Friday at $11.10.Elevate Your Investing...
- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs -
TOKYO , Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced the following changes to its Top Management...
- Supporting Korean Startups' Drug Discovery Research and Global Expansion -
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.
The multibillionaire's portfolio features some moneymaking ideas.
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.
These three biotech stocks were on the volatile side today.
Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue